By utilizing our novel, Artificial Intelligence–based platform (PAREQ, powered by Qlaym), PAREQ aims to advance personalized medicine. Working with our partners, we streamline the development, positioning and lifetime management of new drugs by linking drug efficacy to measurable predictors and by identifying or enriching the critical responder populations. Through the identification of shared systematics of different diseases, we can also strive for additional indications.

The application of a unique Artificial Intelligence method to identify a desired biomarker.

The commercialization of newly defined biomarkers, such as 
“the Cancer States”.

The utilization of comprehen-
sive and high quality tissue collections associated with 
clinical histories for validation.